These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16185572)

  • 1. [Relationships between resistance to cefoxitin, ciprofloxacin and amoxicillin-clavulanic acid in Escherichia coli clinical isolates].
    Fernández-Cuenca F; Amblar G; Pascual A; Martínez-Martínez L
    Enferm Infecc Microbiol Clin; 2005 Oct; 23(8):510-1. PubMed ID: 16185572
    [No Abstract]   [Full Text] [Related]  

  • 2. Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.
    Fernandez-Cuenca F; Martinez-Martinez L; Amblar G; Biedenbach DJ; Jones RN; Pascual A
    Clin Microbiol Infect; 2006 Feb; 12(2):197-8. PubMed ID: 16441464
    [No Abstract]   [Full Text] [Related]  

  • 3. Susceptibility testing of Escherichia coli isolates from urines: are we at risk of reporting false antibiotic resistance to co-amoxiclav?
    Bond A; Plumb H; Turner P
    J Antimicrob Chemother; 2012 Jun; 67(6):1557-8. PubMed ID: 22334608
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain.
    Oteo J; Campos J; Lázaro E; Cuevas O; García-Cobos S; Pérez-Vázquez M; de Abajo FJ;
    Emerg Infect Dis; 2008 Aug; 14(8):1259-62. PubMed ID: 18680650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].
    Martín-Pozo A; Alós JI
    Rev Esp Quimioter; 2012 Sep; 25(3):222-3. PubMed ID: 22987271
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds.
    Gracia M; Ponte C; Soriano F
    Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasmid-Mediated Colistin Resistance Gene mcr-1 in an Escherichia coli ST10 Bloodstream Isolate in the Sultanate of Oman.
    Mohsin J; Pál T; Petersen JE; Darwish D; Ghazawi A; Ashraf T; Sonnevend A
    Microb Drug Resist; 2018 Apr; 24(3):278-282. PubMed ID: 28799833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Inhibitor-Resistant TEM β-Lactamases and Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates.
    Ríos E; López MC; Rodríguez-Avial I; Pena I; Picazo JJ
    Microb Drug Resist; 2015 Oct; 21(5):512-5. PubMed ID: 25945693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Resistance of Escherichia coli isolated from the urinary tract to amoxicillin-clavulanic acid and other antibiotics].
    Ferjani A; Marzouk M; Ben Moussa F; Boukadida J
    Med Mal Infect; 2010 Mar; 40(3):161-4. PubMed ID: 19616395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain.
    Gobernado M; Valdés L; Alós JI; García-Rey C; Dal-Ré R; García-de-Lomas J;
    Rev Esp Quimioter; 2007 Mar; 20(1):68-76. PubMed ID: 17530038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms.
    Rodríguez-Martínez JM; Ballesta S; Pascual A
    Int J Antimicrob Agents; 2007 Oct; 30(4):366-8. PubMed ID: 17616359
    [No Abstract]   [Full Text] [Related]  

  • 13. High percentage of resistance to ciprofloxacin and qnrB19 gene identified in urinary isolates of extended-spectrum beta-lactamase-producing Escherichia coli in Madrid, Spain.
    Ríos E; Rodríguez-Avial I; Rodríguez-Avial C; Hernandez E; Picazo JJ
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):380-3. PubMed ID: 20638608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive culture for extended-spectrum β-lactamase during acute prostatitis after prostate biopsy is a risk factor for progression to chronic prostatitis.
    Oh MM; Chae JY; Kim JW; Kim JW; Yoon CY; Park MG; Moon du G
    Urology; 2013 Jun; 81(6):1209-12. PubMed ID: 23601450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens.
    Vanhoof R; Carpentier M; Delannoy P; Fagnart O; Lontie M; Mans I; Nyssen HJ; Van Nimmen L
    Acta Clin Belg; 2001; 56(1):32-7. PubMed ID: 11307481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 18. Antimicrobial susceptibility patterns of clinical Escherichia coli isolates from dogs and cats in the United States: January 2008 through January 2013.
    Thungrat K; Price SB; Carpenter DM; Boothe DM
    Vet Microbiol; 2015 Sep; 179(3-4):287-95. PubMed ID: 26165272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?
    Patry I; Hocquet D; Talon D; Plesiat P; Bertrand X
    Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli.
    María DA; María-Isabel M; María-Carmen C; Álvaro P; Jorge C; Luis MM; Francesc M; Jordi V; Adriana O; Jesús O; Rafael C
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):334-6. PubMed ID: 26830054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.